Details of the Drug Reposition

General Information of This Drug (ID: DMW6C81)

Drug Name
Eltoprazine   DMW6C81
Synonyms Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Attention deficit hyperactivity disorder DISL8MX9 6A05.Z Phase 3 [1]
------------------------------------------------------------------------------------
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 2 [2]
Parkinson disease DISQVHKL 8A00.0 Phase 2 [3]
Alzheimer disease DISF8S70 8A20 Phase 2 [3]
Dyskinesia DISWDE4R MB47.4 Phase 2 [4]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01266174) Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)